Seminars in Hematology
Volume 44, Issue 4 , Pages 274-277 , October 2007

Autologous Stem Cell Transplantation in Myelodysplastic Syndromes

  • Theo de Witte

      Affiliations

    • Department of Hematology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands.
    • Corresponding Author InformationAddress correspondence to Theo de Witte, MD, Department of Hematology, Radboud University Medical Centre Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
    • ,
  • Stefan Suciu

      Affiliations

    • Leukemia Group, European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium.
    • ,
  • Ronald Brand

      Affiliations

    • Department of Medical Statistics, University of Leiden, Leiden, The Netherlands.
    • ,
  • Petra Muus

      Affiliations

    • Department of Hematology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands.
    • ,
  • Nicolaus Kröger

      Affiliations

    • Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

References 

  1. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: A scoring system with prognostic significance. Br J Haematol. 1985;59:425–433
  2. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199
  3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  4. Maes B, Meeus P, Michaux L, et al. Application of the International Prognostic Scoring System for myelodysplastic syndromes. Ann Oncol. 1999;10:825–829
  5. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November, 1997. Hematol J. 2000;1:53–66
  6. de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000;110:620–630
  7. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100:1201–1207
  8. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–585
  9. Oosterveld M, Suciu S, Verhoef G, et al. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: Results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia. 2003;17:859–868
  10. Oosterveld M, Muus P, Suciu S, et al. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia. 2002;16:1615–1621
  11. de Witte T, van Biezen BA, Hermans J, et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation). Blood. 1997;90:3853–3857
  12. Kroger N, Brand R, van Biezen A, et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2006;37:183–189
  13. Wattel E, Solary E, Leleu X, et al. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes (Groupe Francais des Myelodysplasies. Group Ouest-Est d’etude des Leucemies aigues myeloides). Leukemia. 1999;13:524–529
  14. de Witte T, Suciu S, Verhoef G, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood. 2001;98:2326–2331
  15. Ducastelle S, Ades L, Gardin C, et al. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Haematologica. 2006;91:373–376
  16. Pedersen-Bjergaard J, Specht L, Larsen SO, et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin’s disease (Relation to age, cumulative dose of alkylating agents, and time from chemotherapy). Lancet. 1987;2:83–88
  17. Rubin CM, Arthur DC, Woods WG, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy. Blood. 1991;78:2982–2988
  18. Pedersen-Bjergaard J, Philip P, Larsen SO, et al. Therapy-related myelodysplasia and acute myeloid leukemia (Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series). Leukemia. 1993;7:1975–1986
  19. Ballen KK, Antin JH. Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes. Hematol Oncol Clin North Am. 1993;7:477–493
  20. Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am. 1993;7:81–107
  21. Quesnel B, Kantarjian H, Bjergaard JP, et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): A report on 25 cases and review of the literature. J Clin Oncol. 1993;11:2370–2379
  22. Yakoub-Agha I, de la Salmonière P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients—Report of the French Society of Bone Marrow Transplantation. J Clin Oncol. 2000;18:963–971
  23. Delforge M, Demuynck H, Vandenberghe P, et al. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood. 1995;86:3660–3667
  24. Demuynck H, Delforge M, Verhoef GE, et al. Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol. 1996;92:351–359
  25. de Witte TM, Hagemeijer A, Suciu S, et al. Allogeneic (Allo-) or autologous (Auto-) peripheral blood stem cell transplantation (SCT) randomized versus a second intensive consolidation course in patients with bad prognosis myelodysplastic syndromes and acute myelogenous leukemia following MDS of more than 6 months duration: The final analysis of a joint study (Criant) of the EORTC, EBMT, SAKK, HOVON, and GIMEMA Leukemia groups. Blood. 2005;106:794;(abstr)
  26. Span LF, de Witte TM. Biology of stem and myeloid progenitor cells in myelodysplastic syndromes. Cancer Treat Res. 2001;108:45–63
  27. Carella AM, Dejana A, Lerma E, et al. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol. 1996;95:127–130
  28. de Witte T, Brand R, van Biezen, et al: Peripheral stem cells are the preferred souce of stem cells for autologous stem cell transplantation (ASCT) of young patients with MDS or AML following MDS: An analysis of the chronic leukemia working party of the European Blood and Marrow Transplantation Group (EBMT). Blood 97:848a, (abstr 3525)
  29. de Witte T, Brand R, van Biezen A, et al. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. Haematologica. 2006;91:750–756

 Supported in part by the European Leukemia Net (LSH-2002-2.2.0-3).

PII: S0037-1963(07)00123-0

doi: 10.1053/j.seminhematol.2007.08.006

Seminars in Hematology
Volume 44, Issue 4 , Pages 274-277 , October 2007

Article Tools

* Image Usage & Resolution